The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease

Abstract Background: Metabolic-associated fatty liver disease (MAFLD) is an increasingly prevalent cause of chronic liver disease. In 2020, the FibroScan-AST (FAST) score was internationally validated as a new tool able to identify patients with steatohepatitis who benefit the most from further therapies, based on liver transient elastography (LTE) findings and serum levels of aspartate aminotransferase (AST). We aimed to identify, in MAFLD patients, which metabolic features may predict a higher FAST score. Methods: Retrospective study of consecutive patients with MAFLD submitted to LTE for two consecutive years. Patients without an AST sample collected within 6 months of the LTE were excluded. FAST score was calculated, stratifying the patient’s risk as low (<0.35), medium (0.35-0.67), or high (>0.67). Results: The sample included 117 patients, 53.0% of the female gender, with a mean age of 53 years. On multivariate analysis, patients with type 2 diabetes (T2DM) (p < 0.001), dyslipidemia (p = 0.046), and smoking habits (p = 0.037) presented with significantly higher FAST score values. Furthermore, diabetic patients did not only present significantly higher FAST scores but were also more frequently assigned to the high-risk group according to FAST score criteria (OR = 9.2; 95% CI = 1.8-45.5; p = 0.007). Conclusions: Calculating the FAST score, patients with T2DM presented a significantly higher risk of having significant fibrosis and steatohepatitis. Physicians may rely on this validated instrument to more easily identify which patients with T2DM and MAFLD benefit the most from a specialized follow-up.

Saved in:
Bibliographic Details
Main Authors: Silva,Vítor Macedo, Freitas,Marta, Xavier,Sofia, Carvalho,Pedro Boal, Magalhães,Joana, Marinho,Carla, Cotte,José
Format: Digital revista
Language:English
Published: Sociedade Portuguesa de Gastrenterologia 2023
Online Access:http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452023000600020
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2341-45452023000600020
record_format ojs
spelling oai:scielo:S2341-454520230006000202024-03-18The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver DiseaseSilva,Vítor MacedoFreitas,MartaXavier,SofiaCarvalho,Pedro BoalMagalhães,JoanaMarinho,CarlaCotte,José Metabolic-associated fatty liver disease Liver transient elastography Hepatology Abstract Background: Metabolic-associated fatty liver disease (MAFLD) is an increasingly prevalent cause of chronic liver disease. In 2020, the FibroScan-AST (FAST) score was internationally validated as a new tool able to identify patients with steatohepatitis who benefit the most from further therapies, based on liver transient elastography (LTE) findings and serum levels of aspartate aminotransferase (AST). We aimed to identify, in MAFLD patients, which metabolic features may predict a higher FAST score. Methods: Retrospective study of consecutive patients with MAFLD submitted to LTE for two consecutive years. Patients without an AST sample collected within 6 months of the LTE were excluded. FAST score was calculated, stratifying the patient’s risk as low (<0.35), medium (0.35-0.67), or high (>0.67). Results: The sample included 117 patients, 53.0% of the female gender, with a mean age of 53 years. On multivariate analysis, patients with type 2 diabetes (T2DM) (p < 0.001), dyslipidemia (p = 0.046), and smoking habits (p = 0.037) presented with significantly higher FAST score values. Furthermore, diabetic patients did not only present significantly higher FAST scores but were also more frequently assigned to the high-risk group according to FAST score criteria (OR = 9.2; 95% CI = 1.8-45.5; p = 0.007). Conclusions: Calculating the FAST score, patients with T2DM presented a significantly higher risk of having significant fibrosis and steatohepatitis. Physicians may rely on this validated instrument to more easily identify which patients with T2DM and MAFLD benefit the most from a specialized follow-up.info:eu-repo/semantics/openAccessSociedade Portuguesa de GastrenterologiaGE-Portuguese Journal of Gastroenterology v.30 n.6 20232023-12-01info:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452023000600020en10.1159/000527027
institution SCIELO
collection OJS
country Portugal
countrycode PT
component Revista
access En linea
databasecode rev-scielo-pt
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Silva,Vítor Macedo
Freitas,Marta
Xavier,Sofia
Carvalho,Pedro Boal
Magalhães,Joana
Marinho,Carla
Cotte,José
spellingShingle Silva,Vítor Macedo
Freitas,Marta
Xavier,Sofia
Carvalho,Pedro Boal
Magalhães,Joana
Marinho,Carla
Cotte,José
The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease
author_facet Silva,Vítor Macedo
Freitas,Marta
Xavier,Sofia
Carvalho,Pedro Boal
Magalhães,Joana
Marinho,Carla
Cotte,José
author_sort Silva,Vítor Macedo
title The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease
title_short The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease
title_full The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease
title_fullStr The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease
title_full_unstemmed The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease
title_sort new fibroscan-ast (fast) score: enhancing diabetes mellitus impact on metabolic-associated fatty liver disease
description Abstract Background: Metabolic-associated fatty liver disease (MAFLD) is an increasingly prevalent cause of chronic liver disease. In 2020, the FibroScan-AST (FAST) score was internationally validated as a new tool able to identify patients with steatohepatitis who benefit the most from further therapies, based on liver transient elastography (LTE) findings and serum levels of aspartate aminotransferase (AST). We aimed to identify, in MAFLD patients, which metabolic features may predict a higher FAST score. Methods: Retrospective study of consecutive patients with MAFLD submitted to LTE for two consecutive years. Patients without an AST sample collected within 6 months of the LTE were excluded. FAST score was calculated, stratifying the patient’s risk as low (<0.35), medium (0.35-0.67), or high (>0.67). Results: The sample included 117 patients, 53.0% of the female gender, with a mean age of 53 years. On multivariate analysis, patients with type 2 diabetes (T2DM) (p < 0.001), dyslipidemia (p = 0.046), and smoking habits (p = 0.037) presented with significantly higher FAST score values. Furthermore, diabetic patients did not only present significantly higher FAST scores but were also more frequently assigned to the high-risk group according to FAST score criteria (OR = 9.2; 95% CI = 1.8-45.5; p = 0.007). Conclusions: Calculating the FAST score, patients with T2DM presented a significantly higher risk of having significant fibrosis and steatohepatitis. Physicians may rely on this validated instrument to more easily identify which patients with T2DM and MAFLD benefit the most from a specialized follow-up.
publisher Sociedade Portuguesa de Gastrenterologia
publishDate 2023
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452023000600020
work_keys_str_mv AT silvavitormacedo thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT freitasmarta thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT xaviersofia thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT carvalhopedroboal thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT magalhaesjoana thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT marinhocarla thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT cottejose thenewfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT silvavitormacedo newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT freitasmarta newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT xaviersofia newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT carvalhopedroboal newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT magalhaesjoana newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT marinhocarla newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
AT cottejose newfibroscanastfastscoreenhancingdiabetesmellitusimpactonmetabolicassociatedfattyliverdisease
_version_ 1794800839118815232